Generation of a unique strain of multiple intestinal neoplasia (Apc +/Min-FCCC) mice with significantly increased numbers of colorectal adenomas

Molecular Carcinogenesis

Volumn 44, Issue 1, 2005, Pages 31-41

  Cooper, Harry S ^a   Chang, Wen Chi L ^a   Coudry, Renata ^a   Gary, Monique A ^a   Everley, Lynette ^a   Spittle, Cynthia S ^a   Wang, Hao ^a   Litwin, Sam ^a   Clapper, Margie L ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b Fox Chase Center   (United States)

Author keywords

Animal models of colorectal neoplasia; Chemoprevention; Colorectal neoplasia; Colorectal polyps

Indexed keywords

APC PROTEIN; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; COLORECTAL ADENOMA; CONTROLLED STUDY; DISEASE MODEL; DNA MODIFICATION; EVALUATION; FEMALE; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; INTESTINE CARCINOMA; MALE; MARKER ASSISTED BREEDING; MOUSE; MOUSE STRAIN; MULTIGENE FAMILY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECTUM PROLAPSE; SMALL INTESTINE CANCER; STATISTICAL SIGNIFICANCE; STRAIN IDENTIFICATION;

ADENOMA; ANIMALS; BREAST NEOPLASMS; CECAL NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENES, APC; INCIDENCE; MALE; MICE; RECTAL PROLAPSE;

ANIMALIA; RODENTIA;

EID: 24044487605     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/mc.20114     Document Type: Article

References (65)

1. Rustgi AK. Hereditary gastrointestinal polyposis and non-polyposis syndromes. N Engl J Med 1994;331:1694-1702.
2. Grove EFC, Lamlum H, Crabtree M, et al. Mutation Cluster Region, Association between germline and somatic mutations and genotype phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol 2002; 160:2055-2061.
3. Houlston R, Crabtree M, Phillips R, Tomlinson I. Explaining differences in the severity of familial adenomatous polyposis in the search for modifier genes. Gut 2001;48:1-5.
4. Giardello FM, Krush AJ, Petersen GM, et al. Phenotypic variability of familial adenomatous polyposis in eleven unrelated families with identical Apc gene mutation. Gastro-enterology 1994;106:1542-1547.
5. Heinimann K, Mulhaupt B, Weber W, et al. Phenotypic differences in familial adenomatous polyposis based on APC gene mutation status. Gut 1998;43:675-679.
6. Rozen P, Samuel Z, Shomrat R, Legum C. Notable intrafamilial phenotypic variation in a kindred with familial adenomatous polyposis and an APC mutation in exon 9. Gut 1999;45:827-833.
7. Smits R, Vanderhouvenvanoordt W, Luz A, et al. Apc 1638N: A mouse model for familial adenomatous polyposis-associated desmoid tumors and cutaneous cysts. Gastroenterology 1998;114:275-283.
8. Fodde R, Smits R, Clevers H. Apc, signal transduction and genetic instability in colorectal cancer. Nat Rev 2001;1: 55-67.
9. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity in abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad 1995;92:4482-4486.
10. Δ/716 knockout mice. Cancer Res 1997;57:1644-1649.
11. Yang K, Edelman NW, Lau K, et al. A mouse model of human familial adenomatous polyposis. J Exp Zool 1997;277:245-254.
12. Moser AR, Pitot HC, Dove WF. Dominant mutation that predisposes multiple intestinal neoplasia in the mouse. Science 1990;247:322-324.
13. Shoemaker R, Gould KA, Luongo C, Moser AR, Dove WF. Studies of neoplasia in the Min mouse. Biochemica et Biophysica Acta 1997;1332:F25-F48.
14. Gould KA, Dove WF. Localized gene action controlling ntestinal neoplasia in mice. Proc Natl Acad Sci 1997;94: 5848-5853.
15. AKR intestinal tumor resistance region consists of pla2g2a and a locus distal to D4Mit64. Oncogene 2000;19:3182-3192.
16. Silverman KA, Koratkar E, Siracusa LD, Buchberg AM. Identification of the modifier of Min II (MOM 2) locus. A new mutation that influences Apc induced intestinal neoplasia. Genome Res 2002;12:88-97.
17. Koratkar R, Dequignot E, Hauck WW, Siracusa LD. The CAST/ Ei strain confers significant protection against Apc (Min) intestinal polyps, independent of the resistant modifier of Min1 (Mom1) locus. Cancer Res 2002;62:5413-5417.
18. Min mutation in intestine and mammary gland. Cancer Res 2003;63:4533-4537.
19. Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-670.
20. Corpet DE, Pierre F. Point: From animal models to prevention of colon cancer. Systematic review of chemoprevention in Min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev 2003;12:391-400.
21. Boolbol SK, Dannenberg AJ, Chadburn NA, et al. Cyclooxygenase-II overexpression and tumor formation are blocked by Sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-2560.
22. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998;114: 873-877.
23. Wasan HS, Novelli M, Bee J, Bodmer WF. Dietary fat influences on polyp phenotype in multiple intestinal neoplasia mice. Proc Natl Acad Sci USA 1997;94:3308-3313.
24. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. Cyclooxygenase II inhibitor celecoxib as a preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-5044.
25. Pierre F, Perrin P, Schamp M, Bornet F, Mefla HK, Menante AUJ. Short chain fructo-oligosaccharides reduces the occurrence of colon tumors and development of gut associated lymphoid tissue in the Min mice. Cancer Res 1997;57:225-228.
26. Min/+ mouse. Gastroenterology 2001;121:889-899.
27. Paulsen JE, Steffensen I-L, Loberg EM, Husoy T, Namork E, Alexander J. Qualitative and quantitative relationship between dysplastic aberrant crypt foci and tumorigenesis in the Min/+ mouse. Cancer Res 2001;61:5010-5015.
28. AKR resistant allele. Cancer Res 2000;60:3965-3970.
29. Davis CD, Zeng H, Finley JW. Selenium-enriched broccoli decreases intestinal tumorigenesis in multiple intestinal neoplasia mice. J Nutr 2002;132:307-309.
30. LeFebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57 BL/6J-/Apc Min/positive mice. Nat Med 1998;4:1053-1057.
31. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutch K, Cole CE, Lubetr A, Kelloff GJ, Verna A, Moser AR, Dove WF. Chemoprevention of spontaneous intestinal adenomas in the APC Min mouse model by the non-steroidal antiinflammatory drug Piroxicam. Cancer Res 1996;56:710-714.
32. -/+ mouse model of familial adenomatous polyposis. Cancer Res 2001;61:625-631.
33. Min mouse. Clin Cancer Res 1999;5: 855-863.
34. Van Kranen HJ, Van Ierselp WC, Rijnkels JM, Beems DB, Alink GM, Van Kreijl CF. Effects of dietary fat in vegetable fruit mixture in the development of intestinal neoplasia in the Apc Min mouse. Carcinogenesis 1998;19:1597-1601.
35. Lal G, Ash C, Hay K, et al. Suppressed intestinal polyps in the Msh2-deficient and non-Msh2 deficient multiple intestinal neoplasia mice by a specific cyclo-oxygenase-2 inhibitor and by a dual cyclo-oxygenase 1/2 inhibitor. Cancer Res 2001;61: 6131-6136.
36. Roose J, Huls G, van Brest M , et al. Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. Science 1999;285:1923-1926.
37. Kennedy AR, Beazer-Barclay Y, Kinzler KW, Newburne PM. Suppression of carcinogenesis in the intestines of Min mice by the soybean derived Bowman-Birk inhibitor. Cancer Res 1996;56:679-682.
38. Paulsen JE, Steffensen I-L, Andrassen A, Vikse R, Alexander J. Neonatal exposure to food mutagen 2-amino-1 methyl-6-phenylimidazol [4,5,6] pyridine via breast milk or directly induces intestinal tumors in multiple intestinal neoplasia mice. Carcinogenesis 1999;20:1277-1282.
39. Song J, Medline A, Mason JB, Gallinger S, Kim YI. Effects of dietary folate on intestinal tumorigenesis in the Apc Min mouse. Cancer Res 2000;60:5434-5440.
40. Novelli MR, Wasan H, Rosewel I, et al. Tumor burden and clonality in multiple intestinal neoplasia mouse/normal mouse aggregation chimeras. Proc Natl Acad Sci 1999;96: 12553-12558.
41. /+ mouse model of familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2002;11:535-540.
42. Kakuni M, Morimura K, Wanibuchi A, et al. Food restriction inhibits the growth in intestinal polyps in multiple intestinal neoplasia mouse. JPN J Cancer Res 2002;93:236-241.
43. Saez E, Tibtibez P, Nelson MC, et al. Activators of the nuclear receptor PPAR Gamma enhanced colon polyp formation. Nat Med 1998;4:1058-1061.
44. Boivin GP, Washington K, Yang K, et al. Pathology of mouse models of intestinal cancer: Consensus report and recommendations. Gastroenterology 2003;124:762-777.
45. Rosner A, Miyoshi K, Landesman-Bollag E, et al. Histological differences between ErbB/Ras and Wnt Pathway transgenic mammary tumors. Am J Pathol 2002;161:1087-1097.
46. Min-induce intestinal neoplasia. Cell 1995;81:957-966.
47. Δ/716 knockout mice. Carcinogenesis 1997;18:1863-1865.
48. Spiro L, Olschwang S, Groden J, et al. Alleles of the APC gene: An attenuated form of familial polyposis. Cell 1993;75:951-957.
49. Friedl W, Meuschel S, Caspari R, et al. Attenuated familial adenomatous polyposis due to a mutation in the 3 prime part of the APC gene. A clue from understanding the function of the APC protein. Hum Genet 1996;97:579-584.
50. Dove WF, Clipson L, Gould KA, et al. Intestinal neoplasia in the Apc Min mouse: Independence from the microbial and natural killer (Beige Locus) status. Cancer Res 1997;57:812-814.
51. Clark JC, Collan Y, Edie TJ, et al. Prevalence of polyps in an autopsy series from areas with varying incidence of large bowel cancers. In J Cancer 1985;36:179-180.
52. Coode PE, Chan KW, Chan YT. Polyps and diverticula of the large intestine: A necropsy survery in Hong Kong. Gut 1985; 26:1045-1048.
53. Weyant MJ, Carothers AM, Mahmoud NN, et al. Reciprocal expression of ER alpha and ER beta is associated with estrogen mediated modulation of intestinal tumorigenesis. Cancer Res 2001;61:2547-2551.
54. Woodson K, Lanza E, Tangrea JA, et al. Hormone replacement therapy in colorectal adenoma recurrence among women in the polyp prevention trial. J NCI 2001;93:1799-1805.
55. Martinez NE. Hormone replacement therapy and adenoma recurrence: Implications for its role in colorectal cancer risk. J NCI 2001;93:1764-1765.
56. Grodstein F, Newcomb A, Stampfer MJ. Post-menopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med 1999;106:574-582.
57. Chen MJ, Longnecker MP, Morganstern H, Lee ER, Frankl HD, Hailer W. Recent use of hormone replacement therapy in the prevalence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1998;7:227-230.
58. Potter JD, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: Minnesota cancer prevention research unit case control study. Cancer Epidemiol Biomarkers Prev 1996;5:779-784.
59. Peipins LA, Newman B, Sandler RS. Reproductive history, use of exogenous hormones, risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1997;6:671-675.
60. Cooper HS, Everley L, Chan WC, et al. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium induced colitis. Gastroenterology 2001;121:1407-1416.
61. Min/+ mice. Cancer Res 2002;62:6367-6370.
62. Luongo C, Moser AR, Gledhill S, Dove WF. Loss of Apc+ in intestinal adenomas from Min mice. Cancer Res 1994;54: 5947-5952.
63. Levy DB, Smith KJ, Beazer-Barclay Y, Hamilton SR, Vogelstein B, Kinzler KW. IInactivation of both APC alleles in human and mouse tumors. Cancer Res 1994;54:5953-5958.
64. Powell SM, Zilz N, Beazer-Barclay Y, et al. Apc mutations occur early during colorectal carcinogenesis. Nature 1992; 359:235-237.
65. Miyoshi Y, Nagase H, Ando H, et al. Somatic mutations of the Apc gene in colorectal tumors; mutation cluster region in the APC gene. Hum Mol Genet 1992;1:229-233.